MedTrace Logo

Effect of Momordica Charantia Administration on Anthropometric Indicators in Patients With Obesity

NCT04916379 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-08-31

No results posted yet for this study

Summary

Momordica charantia has shown to exert anti-obesity effects through numerous mechanisms of action described in preclinical studies. Important reductions in body weight and other anthropometric indicators have been reported in clinical trials. However, these beneficial effects of Momordica charantia on obesity have been observed mainly in type 2 diabetes mellitus patients. The purpose of this study is to evaluate the effect of Momordica charantia administration on anthropometric indicators in patients with obesity.

Conditions

Interventions

DIETARY_SUPPLEMENT

Momordica charantia

Momordica Charantia: 2000 mg per day for 12 weeks

OTHER

Placebo

Placebo: 2000 mg per day for 12 weeks

Sponsors & Collaborators

  • University of Guadalajara

    lead OTHER

Principal Investigators

  • Marisol Cortez Navarrete, PhD · Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-21
Primary Completion
2021-09-30
Completion
2021-09-30

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04916379 on ClinicalTrials.gov